Overview

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Status:
Completed
Trial end date:
2019-05-02
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genmab
Seagen Inc.
Collaborator:
Genmab
Treatments:
Tisotumab vedotin